<?xml version="1.0" encoding="UTF-8"?>
<p id="par0155">The nascent field of cancer “virotherapy” exploits the ability of viruses to replicate selectively in malignant cells as a novel approach to killing tumors. To monitor the replication of the oncolytic virus, recombinant agents have been constructed that encode a reporter for radionuclide imaging. Examples include:
 <list list-type="simple" id="lis0010">
  <list-item id="lsti0025">
   <label>•</label>
   <p id="par0160">a recombinant vaccinia virus encoding the human norepinephrine transporter, which enables PET imaging by causing
    <sup>124</sup>I-meta-iodobenzylguanidine (MIBG) to accumulate within infected cells (
    <xref rid="fig0040" ref-type="fig">Fig. 8</xref> ) (
    <xref rid="bib0110" ref-type="bibr">Chen et al., 2009b</xref>);
   </p>
  </list-item>
  <list-item id="lsti0030">
   <label>•</label>
   <p id="par0165">a recombinant vaccinia virus encoding the type-2 somatostatin receptor, which binds the somatostatin analog 
    <sup>111</sup>In-pentetreotide on the cell surface, so that virus-infected tumors can be imaged by gamma scanning (
    <xref rid="bib0390" ref-type="bibr">McCart et al., 2004</xref>);
   </p>
  </list-item>
  <list-item id="lsti0035">
   <label>•</label>
   <p id="par0170">recombinant measles and vesicular stomatitis viruses encoding the thyroidal sodium iodide symporter, which causes infected cells to take up 
    <sup>123</sup>I for PET imaging, or 
    <sup>131</sup>I for radiotherapy (
    <xref rid="bib0175" ref-type="bibr">Dingli et al., 2004</xref>, 
    <xref rid="bib0265" ref-type="bibr">Goel et al., 2007</xref>). Herpesviruses are also being used as experimental oncolytic agents; in this case, the virus’ own TK provides a reporter for PET or SPECT imaging (see below).
   </p>
  </list-item>
 </list>
</p>
